Skip to main content

AbbVie Inc. Immunology revenue

  • ABBV · NYSE
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$295.03+0.20%Close 13 Nov 2026 · Market value $524.5B

Immunology revenue at AbbVie Inc. came to $9.2B for the quarter to 30 Sep 2026, up 16.2% from a year earlier.

As AbbVie Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$7.0BDec 2023$5.4BMar 2024$7.0BJun 2024$7.0BSep 2024$7.3BDec 2024$6.3BMar 2025$7.6BJun 2025$7.9BSep 2025$8.6BDec 2025$7.3BMar 2026$8.8BJun 2026$9.2BSep 2026
AbbVie Inc. Immunology revenue, every reported period
Period endingImmunology revenueChange on a yearFiled
30 Sep 2026$9.2Bup 16.2%30 Oct 2026
30 Jun 2026$8.8Bup 15.1%31 Jul 2026
31 Mar 2026$7.3Bup 16.4%29 Apr 2026
31 Dec 2025$8.6Bup 18.3%4 Feb 2026
30 Sep 2025$7.9Bup 11.9%31 Oct 2025
30 Jun 2025$7.6Bup 9.5%31 Jul 2025
31 Mar 2025$6.3Bup 16.6%25 Apr 2025
31 Dec 2024$7.3Bup 4.9%31 Jan 2025
30 Sep 2024$7.0Bup 3.9%30 Oct 2024
30 Jun 2024$7.0Bup 2.3%25 Jul 2024
31 Mar 2024$5.4Bdown 3.9%26 Apr 2024
31 Dec 2023$7.0Bdown 12.3%2 Feb 2024
30 Sep 2023$6.8B—27 Oct 2023
30 Jun 2023$6.8B—27 Jul 2023
31 Mar 2023$5.6B—27 Apr 2023
31 Dec 2022$7.9B—9 Feb 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of AbbVie Inc.: Skyrizi revenue · Rinvoq revenue · Botox Therapeutic revenue · Vraylar revenue · Venclexta revenue · Humira revenue · Botox Cosmetic revenue · Imbruvica revenue · Ubrelvy revenue · Qulipta revenue · Creon revenue · Vyalev revenue · Mavyret revenue · Elahere revenue · Juvederm Collection revenue · Linzess/Constella revenue · Ozurdex revenue · Epkinly revenue · Lumigan/Ganfort revenue · Duodopa revenue · Alphagan/Combigan revenue · Neuroscience revenue · Oncology revenue · Aesthetics revenue · financial statements

Every KPI and segment of ABBV, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.